BioCardia Inc (BCDA)

[realfast95]

The trade case here is that BCDA will apply for listing on the Nasdaq soon. They have the independent directors already.

CardiAMP should push for RMAT, regenerative, FDA designation.

The competitor Vericel (VCEL) ixCELL-DCM already has RMAT.
However the FDA stopped them from getting approval for the product until they run a Phase 3 trial. They said they can't without a partner to pay for it. I comes down to the 6 minute walk test.
ixCELL-DCM failed to achieve it in Phase 2. It's the primary endpoint for CardiAMP in this Phase 3 trial.